• Brom Marine

  • ​Brom Marine is a spin-off from TU Bergakademie Freiberg (Technical University of Mining and Technology) in Germany with the aim of developing novel methods in marine biotechnology, marine biomaterials science, as well as encouraging research into the marine pharmacology of sponges. We utilize marine sponges of the Verongida order, which are renewable sources of both the pharmacophore Bromotyrosine and chitinous scaffolds. Bromotyrosines are essential ingredients for many synthetic pathways in marine pharmacology and the scaffolds are needed for tissue engineering applications with both human stem cells and chondrocytes. As such, BromMarin simultaneously extracts highly purified bromotyrosine metabolites in addition to the unique tubular chitinous scaffolds, resulting in maximized usage of this renewable marine resource.

• GlycoMar

  • ​GlycoMar is an innovative biotechnology company that discovers and develops anti-inflammatory drugs based upon the glycobiology of marine organisms. GlycoMar is located near Oban, Scotland.

• Perha Pharmaceuticals ("From Sea to Pharmacy")

  • ​Perha Pharmaceuticals is a development-stage pharmaceutical company engaged in the discovery and development of small molecule drugs (protein kinase inhibitors) against severe pathologies, namely induced hearing loss, neurodegenerative disorders (Alzheimer's diseases, Down syndrome), or renal diseases (Polycystic Kidney Disease). Perha Pharmaceuticals was founded by Dr. Laurent Meijer, from its parent biotech company, ManRos Therapeutics (focused on Cystic Fibrosis). Over the past decades, Dr. Laurent Meijer has gathered a deep knowledge/experience on protein phosphorylation and the development of pharmacological inhibitors of human disease-relevant protein kinases.

• PharmaMar

  • Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trials for the treatment of solid tumors.  The company was incorporated in 1986 and is based in Madrid, Spain.

​

​

Disclaimer and Additional Terms and Conditions of Use:

 

The descriptions set forth above are not intended to be an endorsement and should not be interpreted as an endorsement of any of the referenced pharmaceutical companies or their products. In addition, if any user or visitor to this webpage (hereinafter "You") decides to visit any linked site set forth herein, You do so at your own risk and it is your responsibility to take all protective measures to guard against viruses or other destructive elements.  The linked sites set forth herein are provided solely as a convenience to You and do not constitute an endorsement of the contents of such sites. You agree that neither marinepharmacology.org nor Dr. Mayer is responsible or liable for any direct or indirect damage or loss caused by or in connection with the use of any content, products or services provided or advertised on a linked site. The marinepharmacology.org and Dr. Mayer make no representations or warranties regarding the content, accuracy, or privacy practices of the linked sites set forth herein. If You are concerned about the privacy practices of an outside site, please consult the site's privacy policy.

​